自己看看这篇文章的作者都是收了谁的钱,我没有证据证明他们的目的,我不会胡说。但大家可以动脑子想想 写这文章的背后可能的目的是啥。 Notes Financial support. This study was supported by Gilead Sciences (investigator-initiated research study grant). Potential conflicts of interest. R. J. W. has received funding (to his insti- tution) from Gilead Sciences, and has served as a consultant and on the ad- visory board for Gilead Sciences. H. W. K., J. K. N., and H. K. are employees of and H. W. K. and H. K. own stock in Quest Diagnostics. R. G. G. reports grants received from Gilead Sciences; has served as an advisor or consultant to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, Venatorx, Prodigy, Fibronostics, Fujifilm/Wako, Perspectum, Quest, and Sonic Incytes; has served on the data safety mon- itoring board for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect; has served on the speaker’s bureau for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; is a minor stock shareholder of RiboSciences and CoCrystal; and has received stock options from Eiger, Genlantis, HepQuant, and AngioCrine. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. |
tim889 发表于 2022-8-4 05:27
所谓的依据原文在这里:Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to El ...
欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |